SCHEMBL1697130

SCHEMBL1697130

CCN1C(=O)[N]C(=O)C=C1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GMNN O75496 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
THPO P40225 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MGLL Q99685 1/20 0.37
F2 P00734 1/20 0.36
ELANE P08246 1/20 0.36
CTSG P08311 1/20 0.36
CTRC Q99895 1/20 0.36
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
CYP19A1 P11511 1/20 0.31
ATAD2 Q6PL18 1/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503560 0.72
SCHEMBL6014095 0.65 F2 (0.37) GMNNALDH1A1LMNAMAPTTHPO
SCHEMBL6014100 0.60 F2 (0.32) F2ELANECTSGCTRC
SCHEMBL8857850 0.60
SCHEMBL7436460 0.59 ALDH1A1 (0.41) GMNNALDH1A1LMNAMAPTTHPO
SCHEMBL4753186 0.59 ALDH1A1 (0.41) GMNNALDH1A1LMNAMAPTTHPO
SCHEMBL19410249 0.58 GMNN (0.34) GMNNALDH1A1LMNAMAPTTHPO
SCHEMBL5455521 0.57
N-Ethylmaleimide SCHEMBL3675197 0.57 MGLL (0.89) GMNNALDH1A1LMNAMAPTTHPO
SCHEMBL12927818 0.56 F2 (1.00) GMNNALDH1A1LMNAMAPTTHPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595630-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION Gilead Sciences, Inc. (US) 2013-05-29 EP disclosed
WO-2012003220-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed
EP-1996201-A2 METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-12-03 EP disclosed
WO-2007109547-A2 METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-27 WO disclosed
EP-1799221-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-06-27 EP disclosed
EP-1789053-A2 METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-05-30 EP disclosed
EP-1685132-A1 A sb 2B /sb ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-08-02 EP disclosed
WO-2006044610-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC (US) 2006-04-27 WO disclosed
WO-2006028810-A2 METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-03-16 WO disclosed
WO-2005051951-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-06-09 WO disclosed